Product
APL-101
2 clinical trials
19 indications
Indication
Solid TumorsIndication
Advanced CancerIndication
Renal Cell CarcinomaIndication
Stomach CancerIndication
Esophageal CancerIndication
NSCLCIndication
lung cancerIndication
Brain TumorIndication
Glioblastoma MultiformeIndication
EGFR gene mutationIndication
MET gene amplificationIndication
Hematopoietic Growth FactorIndication
Thyroid CancerIndication
Pancreatic CancerIndication
Colon CancerIndication
MET AlterationIndication
MET FusionIndication
Exon 14 SkippingIndication
Metastatic Non Small Cell Lung CancerClinical trial
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
Phase I/II Study Exploring the Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2027-09-30